Analysis of loss of heterozygosity in atypical and negative bile duct brushing cytology specimens with malignant outcome: are "false-negative" cytologic findings a representation of morphologically subtle molecular alterations?

Arch Pathol Lab Med. 2007 Jan;131(1):74-80. doi: 10.5858/2007-131-74-AOLOHI.

Abstract

Context: Conventional cytologic evaluation of bile duct brushings for neoplasia has high specificity but relatively low sensitivity.

Objective: The aim of this pilot study was to examine whether K-ras mutations and loss of heterozygosity for multiple microsatellite markers in bile duct brushings would contribute to the detection of malignancy in cases initially reported as "negative" or "atypical."

Design: Bile duct brushing specimens with a negative or an atypical cytologic result (9 cases) had a benign result on the surgical pathology specimen, and 9 additional negative or atypical cases demonstrated adenocarcinoma on the resected surgical specimen. Cells from representative cytopathology and histology slides were microdissected and analyzed for K-ras mutations and for loss of heterozygosity with a panel of 15 polymorphic markers on chromosomes 1p, 3p, 5q, 9p, 9q, 10q, 17p, and 22q.

Results: Among cytology cases with malignant outcome, loss of heterozygosity or K-ras mutation was detected in 8 (88.8%) of 9 cases. In the corresponding 9 surgical pathology specimens with adenocarcinoma, K-ras mutations and/or allelic losses were detected in all (100%). Loss of heterozygosity or K-ras mutation was not detected in cytology cases that had a benign surgical outcome. The fractional allelic loss of these 9 cytology specimens ranged from 0 to 0.25 (mean, 0.14). This compared with the fractional allelic loss ranging from 0.15 to 0.42 (mean, 0.27) for the corresponding surgical specimens.

Conclusions: This pilot study suggests that low-level fractional allelic loss or K-ras mutation in the negative/atypical cytology samples with malignant outcome is a representation of morphologically subtle molecular alterations.

MeSH terms

  • Adenocarcinoma / diagnosis
  • Adenocarcinoma / genetics*
  • Adenocarcinoma / pathology*
  • Adult
  • Aged
  • Aged, 80 and over
  • Alleles
  • Bile Duct Neoplasms / diagnosis
  • Bile Duct Neoplasms / genetics*
  • Bile Duct Neoplasms / pathology*
  • DNA, Neoplasm / genetics
  • False Negative Reactions
  • Female
  • Gene Expression Regulation, Neoplastic
  • Genes, ras / genetics
  • Humans
  • Loss of Heterozygosity / genetics*
  • Male
  • Microsatellite Repeats / genetics
  • Middle Aged
  • Mutation / genetics
  • Pilot Projects
  • Prognosis
  • Sensitivity and Specificity

Substances

  • DNA, Neoplasm